{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-021304","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.502777+00:00","generated_at":"2026-05-23T00:17:42.841269+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"X4 Pharma Q1 net income $0.3M on $28.8M revenue; XOLREMDI sales $3.5M since launch; 4WARD trial on track","bullets":["Q1 net income $0.3M vs loss $51.8M YoY; revenue $28.8M included $27.9M license fee from Norgine.","XOLREMDI cumulative U.S. net sales $3.5M since May 2024 launch through March 2025.","Phase 3 4WARD CN trial full enrollment expected 3Q/4Q 2025; top-line data in 2H 2026.","Strategic restructuring to cut annual spending by $30-35M; cash $87.7M funds ops into 1H 2026.","Completed 1-for-30 reverse stock split effective April 28, 2025; shares reduced from ~173.6M to ~5.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-021304","json":"https://secwatch.observer/filing/0001628280-25-021304.json","markdown":"https://secwatch.observer/filing/0001628280-25-021304.md","text":"https://secwatch.observer/filing/0001628280-25-021304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/0001628280-25-021304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025021304/xfor-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:17:42.841269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}